{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=14", "query": { "intervention": "RAYOS", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1199, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T21:14:09.374Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03345407", "title": "Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Placebo ELLIPTA", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 50 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 100 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 250 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 500 µg", "type": "DRUG" }, { "name": "Nemiralisib ELLIPTA 750 µg", "type": "DRUG" }, { "name": "Albuterol (Salbutamol) MDI or nebules", "type": "DRUG" }, { "name": "Standard of care therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 943, "start_date": "2017-11-28", "completion_date": "2019-01-10", "has_results": true, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 21, "location_summary": "Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Adairsville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345407" }, { "nct_id": "NCT03586999", "title": "Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Oncovin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Hydroxydaunorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 18, "start_date": "2018-11-07", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 3, "location_summary": "Duarte, California • Aurora, Colorado • Philadelphia, Pennsylvania", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03586999" }, { "nct_id": "NCT00540644", "title": "Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "lenalidomide (Revlimid®)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Attaya Suvannasankha", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2007-10", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00540644" }, { "nct_id": "NCT01786265", "title": "Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Nilutamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 310, "start_date": "2013-02-05", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786265" }, { "nct_id": "NCT00156767", "title": "Adrenal Function in Critical Illness", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adrenal Insufficiency" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 225, "start_date": "2004-11-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156767" }, { "nct_id": "NCT03023891", "title": "Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glucocorticoids Toxicity", "Glucose Intolerance" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 25, "start_date": "2017-02-15", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2020-06-04", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03023891" }, { "nct_id": "NCT02036463", "title": "A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy (DMD)" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "6 Years", "sex": "MALE", "summary": "3 Years to 6 Years · Male only" }, "enrollment_count": 0, "start_date": "2014-11", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-02-18", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02036463" }, { "nct_id": "NCT01531205", "title": "Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Androgen Ablation", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Salvage Therapy", "type": "DRUG" }, { "name": "Neoadjuvant Treatment - Hormonal Therapy", "type": "DRUG" }, { "name": "Neoadjuvant Treatment - Cabazitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2, "start_date": "2012-05", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-11-05", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01531205" }, { "nct_id": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2020-06-15", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323956" }, { "nct_id": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Richter's Syndrome", "Treatment-naïve High Risk Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2020-11-25", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-22T21:14:09.374Z", "location_count": 23, "location_summary": "Birmingham, Alabama • California City, California • Duarte, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "California City", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04623541" } ] }